Understanding What Is Non H D L Cand Its Clinical Relevance

Published

Table of Contents

Non-HDL cholesterol (Non-HDL-C) represents a critical yet often underappreciated metric in cardiovascular risk assessment, encompassing all atherogenic lipid particles beyond HDL. Unlike LDL-C, which isolates a single fraction of cholesterol-carrying particles, Non-HDL-C aggregates LDL, VLDL remnants, and IDL—each contributing to arterial plaque formation and systemic inflammation. This composite measure provides a broader snapshot of lipid metabolism, particularly in high-risk populations where traditional markers may underestimate residual cardiovascular threat. By bridging biochemical complexity with clinical utility, Non-HDL-C emerges as a pivotal tool for refining diagnostic precision and guiding evidence-based interventions in lipid management.

The physiological role of Non-HDL-C extends beyond mere cholesterol transport, serving as a dynamic indicator of metabolic dysregulation. Elevated levels signal dyslipidemia, insulin resistance, and endothelial dysfunction, often preceding overt cardiovascular events by years. While LDL-C remains a cornerstone of risk stratification, Non-HDL-C offers distinct advantages in populations with overlapping lipid abnormalities, such as metabolic syndrome or familial hypercholesterolemia, where isolated LDL measurements may obscure critical pathological processes. This dual perspective underscores the need for a nuanced approach to lipid assessment, one that integrates both traditional and emerging biomarkers to address the heterogeneity of atherosclerotic risk.

what is non-hdl-c

Biochemical Composition and Physiological Function of Non-HDL-C

Non-HDL-C represents a composite measure of atherogenic lipoproteins in circulation, excluding only high-density lipoprotein cholesterol (HDL-C). Its biochemical profile includes low-density lipoproteins (LDL-C), very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and lipoprotein remnants—collectively termed "atherogenic particles." Unlike HDL-C, which facilitates reverse cholesterol transport to the liver for excretion, Non-HDL-C particles are primarily responsible for delivering cholesterol to peripheral tissues, including arterial walls. This distinction underscores their central role in lipid metabolism and cardiovascular risk stratification.

The physiological function of Non-HDL-C is intrinsically linked to lipid transport and cholesterol homeostasis. VLDL particles, synthesized in the liver, undergo sequential lipolysis by lipoprotein lipase (LPL), transforming into IDL and ultimately LDL. These remnants, particularly chylomicron remnants (derived from dietary fat), retain apoB-100 or apoB-48 and are enriched in cholesterol esters, triglycerides, and pro-inflammatory phospholipids. While LDL-C is the dominant component (~70–80% of Non-HDL-C in normolipidemic individuals), VLDL remnants and IDL contribute disproportionately to residual cardiovascular risk, even when LDL-C targets are met. Elevated Non-HDL-C reflects either overproduction of atherogenic lipoproteins or impaired clearance, both of which accelerate atherosclerosis through endothelial dysfunction, foam cell formation, and chronic inflammation.

Biochemical Composition of Non-HDL-C and Its Components

Non-HDL-C comprises a heterogeneous population of lipoproteins characterized by their density, size, and apolipoprotein content. The primary constituents include:

- Very Low-Density Lipoproteins (VLDL): Synthesized in the liver, VLDL particles (density <1.006 g/mL) transport endogenous triglycerides (TGs) and cholesterol to peripheral tissues. Their core consists of TGs (50–60%), with smaller proportions of cholesterol esters (10–15%) and phospholipids (7–10%). VLDL remnants, generated after LPL-mediated TG hydrolysis, are enriched in cholesterol and apoE, facilitating hepatic uptake via LDLR or LRP1 pathways.

  • Intermediate-Density Lipoproteins (IDL): Intermediate products of VLDL metabolism (density 1.006–1.019 g/mL), IDL retains ~30% of its original TG content but contains higher proportions of cholesterol esters (25–30%). IDL can either be further processed into LDL or cleared directly by the liver, contributing to postprandial dyslipidemia.
  • Low-Density Lipoproteins (LDL): The most abundant atherogenic particle (density 1.019–1.063 g/mL), LDL consists of ~40% cholesterol esters, 25% proteins (primarily apoB-100), and 10% TGs. LDL particles vary in size (small, dense LDL being more atherogenic) and are the primary carriers of cholesterol to extrahepatic tissues.
  • Lipoprotein Remnants: Chylomicron remnants (density <1.006 g/mL) arise from dietary fat absorption and are particularly enriched in cholesterol and apoB-48. Their delayed clearance due to genetic or metabolic defects (e.g., apoE mutations) is strongly associated with premature coronary artery disease.
    • Key Distinction: Non-HDL-C includes all apoB-containing particles (each carrying one apoB molecule), whereas LDL-C reflects only the mature, LDL-specific fraction. This distinction is critical because apoB quantification provides a more comprehensive measure of atherogenic burden than LDL-C alone.

    Physiological Role in Cholesterol Metabolism and Cardiovascular Risk

    The primary physiological function of Non-HDL-C is to mediate cholesterol delivery to peripheral cells via receptor-independent pathways, including scavenger receptor-mediated uptake by macrophages. This process, while essential for cellular membrane synthesis, becomes maladaptive when excess cholesterol accumulates in arterial walls, forming foam cells and fibrous plaques. Key mechanisms linking elevated Non-HDL-C to atherosclerosis include:

    - Enhanced Lipoprotein Retention: Small, dense LDL and VLDL remnants penetrate the arterial intima more readily than larger particles, promoting subendothelial accumulation.

  • Oxidative Modification: Non-HDL-C particles are susceptible to oxidation, generating pro-inflammatory oxidized LDL (oxLDL) that disrupts endothelial integrity and attracts immune cells.
  • Impaired Clearance: Genetic variants (e.g., PCSK9 gain-of-function mutations) or metabolic conditions (e.g., insulin resistance) reduce hepatic LDLR activity, prolonging the circulation of atherogenic particles.
  • Residual Risk in Statin Therapy: Even with LDL-C lowering, elevated Non-HDL-C reflects persistent exposure to VLDL remnants and IDL, contributing to ~30% of residual cardiovascular risk in statin-treated patients.
    • Clinical Relevance: Non-HDL-C levels ≥130 mg/dL (3.36 mmol/L) are associated with a 2–3-fold increased risk of coronary heart disease, independent of LDL-C. This metric is particularly valuable in patients with metabolic syndrome, diabetes, or familial hypercholesterolemia, where VLDL remnants predominate.

    Comparison of Non-HDL-C and LDL-C: Biochemical and Clinical Differentiation

    The following table contrasts Non-HDL-C and LDL-C across key biochemical and clinical parameters, highlighting their distinct roles in lipid metabolism and cardiovascular risk assessment.

    Clinical Significance and Diagnostic Importance of Non-HDL-C

    Non-HDL-C serves as a comprehensive lipid metric that reflects the total atherogenic lipoprotein burden, including LDL-C, intermediate-density lipoprotein cholesterol (IDL-C), very-low-density lipoprotein cholesterol (VLDL-C), and lipoprotein(a) [Lp(a)]. Unlike LDL-C, which is often influenced by dietary triglycerides or analytical variability, Non-HDL-C provides a broader and more stable assessment of residual cardiovascular risk. Its clinical utility extends beyond traditional lipid profiling, particularly in high-risk populations where LDL-C alone may underestimate atherosclerotic burden. This subtopic examines the conditions where Non-HDL-C offers superior diagnostic precision, its role in risk stratification, and its integration into cardiovascular risk assessment tools.

    Medical Conditions Where Non-HDL-C Provides Superior Diagnostic Value

    Non-HDL-C demonstrates particular diagnostic advantages in metabolic disorders characterized by elevated triglycerides, dyslipidemia, or impaired lipid metabolism. These conditions often involve overlapping or compensatory lipid abnormalities that LDL-C measurements may fail to capture.

    Metabolic Syndrome and Insulin Resistance
    Metabolic syndrome is associated with elevated triglycerides, low HDL-C, and central obesity, creating a lipid profile where LDL-C may be artificially lowered due to triglyceride-rich VLDL particles displacing LDL particles in density gradients. Non-HDL-C accounts for all atherogenic lipoproteins, including VLDL remnants and IDL, which are independently linked to endothelial dysfunction and atherosclerosis in insulin-resistant states. Studies indicate that Non-HDL-C levels in metabolic syndrome patients correlate more strongly with carotid intima-media thickness (CIMT) and subclinical atherosclerosis than LDL-C alone.

    Type 2 Diabetes Mellitus
    Diabetic dyslipidemia—marked by elevated triglycerides, low HDL-C, and small, dense LDL particles—poses a heightened cardiovascular risk. Non-HDL-C better reflects the proatherogenic milieu in diabetes by encompassing remnant lipoproteins, which are associated with increased risk of coronary artery disease (CAD) and stroke. The ACC/AHA guidelines emphasize Non-HDL-C as a secondary target in diabetic patients, particularly when triglycerides exceed 150 mg/dL, where LDL-C may underestimate risk due to analytical challenges (e.g., Friedewald equation inaccuracies).

    Familial Hypercholesterolemia (FH)
    In FH, where LDL receptor dysfunction leads to lifelong elevated LDL-C, Non-HDL-C provides a more comprehensive assessment of genetic lipid burden. Heterozygous FH patients often exhibit elevated VLDL and IDL, which Non-HDL-C captures, whereas LDL-C may not fully represent the total atherogenic load. The Simon Broome Register and Dutch Lipid Clinic Network criteria incorporate Non-HDL-C as a diagnostic adjunct, particularly in children or adults where LDL-C measurements are ambiguous due to concurrent hypertriglyceridemia.

    Additional High-Risk Scenarios

  • Chronic Kidney Disease (CKD): Non-HDL-C better predicts cardiovascular events in CKD patients, where LDL-C is often suppressed due to nephrotic syndrome or lipid-lowering therapy.
  • Postmenopausal Women: Non-HDL-C correlates more strongly with coronary risk than LDL-C, reflecting the shift toward remnant lipoprotein metabolism.
  • HIV/Lipodystrophy Syndromes: Antiretroviral therapy-induced dyslipidemia often elevates VLDL and IDL, making Non-HDL-C a more reliable marker for residual risk.

    • Correlation Between Non-HDL-C Levels and Cardiovascular Risk Stratification

    Non-HDL-C levels stratify cardiovascular risk more effectively than LDL-C in populations with elevated triglycerides or mixed dyslipidemia. The following table categorizes risk levels based on adult treatment panel (ATP) IV and ESC/EAS guidelines, incorporating clinical outcomes and therapeutic implications.
    Parameter Non-HDL-C LDL-C
    Definition Total cholesterol minus HDL-C; includes LDL, VLDL, IDL, and remnants. Cholesterol associated with LDL particles (apoB-100); calculated directly or via Friedewald equation.
    Primary Components
    • LDL-C (~70–80% of Non-HDL-C in normolipidemia)
    • VLDL and remnants (~10–20%)
    • IDL (~5–10%)
    • Chylomicron remnants (postprandial)
    		 Mature LDL particles (apoB-100) with variable size (large/buoyant vs. small/dense).
    Particle Size Range 18–100 nm (heterogeneous; includes large VLDL to small LDL remnants). 18–28 nm (small, dense LDL) to 25–35 nm (large, buoyant LDL).
    Apolipoprotein Content ApoB-100 (LDL, IDL), apoB-48 (remnants), and apoE (VLDL/remnants). Exclusively apoB-100.
    Metabolic Fate
    • VLDL → IDL → LDL (via LPL-mediated lipolysis)
    • Chylomicrons → remnants (via dietary fat absorption)
    • Hepatic clearance via LDLR, LRP1, or SR-B1.
    		 Primarily cleared by LDLR in the liver; small, dense LDL has reduced affinity for LDLR.
    Clinical Relevance
    • Superior predictor of cardiovascular events in metabolic syndrome/diabetes.
    • Reflects total atherogenic burden, including remnant lipoproteins.
    • Targeted by non-statin therapies (e.g., PCSK9 inhibitors, fibrates).
    • Primary target for statin therapy; correlates with coronary risk.
    • Less informative in dysbetalipoproteinemia or hypertriglyceridemia.
    • Underestimates risk when VLDL remnants predominate.
    Measurement Limitations Requires HDL-C measurement; less standardized than LDL-C. Friedewald equation inaccurate at TG ≥400 mg/dL; direct measurement preferred.
    Risk Category Non-HDL-C Range (mg/dL) Associated Health Outcomes Clinical Recommendations
    Low Risk <130 mg/dL
    • Minimal atherosclerotic plaque progression in primary prevention populations.
    • Low incidence of major adverse cardiovascular events (MACE) in individuals without diabetes or CKD.
    • May reflect favorable metabolic profiles (e.g., normal HDL-C, low triglycerides).
    • Lifestyle modification (diet, exercise) sufficient for primary prevention.
    • Re-evaluate if triglycerides >150 mg/dL or HDL-C <40 mg/dL (men) / <50 mg/dL (women).
    Moderate Risk 130–159 mg/dL
    • Moderate subclinical atherosclerosis (e.g., CIMT 0.7–0.9 mm).
    • Increased risk of stable angina or asymptomatic ischemia in secondary prevention.
    • Higher prevalence of metabolic syndrome or pre-diabetes.
    • Statins recommended in high-risk subgroups (e.g., ASCVD risk ≥7.5% or diabetes).
    • Consider ezetimibe or PCSK9 inhibitors if LDL-C remains elevated despite statin therapy.
    • Monitor Non-HDL-C every 3–6 months in uncontrolled dyslipidemia.
    High Risk 160–189 mg/dL
    • Significant atherosclerotic burden (e.g., CIMT ≥0.9 mm, coronary artery calcium score ≥100).
    • Elevated risk of acute coronary syndromes (ACS) and stroke (HR ~1.5–2.0 vs. low-risk group).
    • Common in FH, diabetes with albuminuria, or post-ACS patients.
    • High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg).
    • Add-on therapy (ezetimibe, PCSK9 inhibitors) if Non-HDL-C remains ≥100 mg/dL post-statin.
    • Aggressive glycemic and blood pressure control in diabetic patients.
    Very High Risk >190 mg/dL
    • Severe atherosclerosis (e.g., prior MI, symptomatic CAD, or multiple risk factors).
    • Highest incidence of MACE (HR >2.5 vs. low-risk group); rapid disease progression.
    • Associated with familial dyslipidemia or untreated FH.
    • Maximal tolerated statin dose + ezetimibe + PCSK9 inhibitor (e.g., alirocumab/evocumab).
    • Consider LDL apheresis in refractory FH (Non-HDL-C >220 mg/dL).
    • Cardiology referral for invasive risk assessment (e.g., coronary angiography).
    Key Considerations for Risk Interpretation:
  • Triglyceride Thresholds: Non-HDL-C accuracy declines when triglycerides exceed 400 mg/dL; direct LDL-C measurement is preferred in severe hypertriglyceridemia.
  • Residual Risk: In patients with LDL-C <70 mg/dL but Non-HDL-C >100 mg/dL, remnant lipoprotein therapy (e.g., fibrates, omega-3s) may be warranted.
  • Ethnic Variations: South Asians and Hispanics exhibit higher cardiovascular risk at lower Non-HDL-C thresholds compared to Caucasians.

    • Integration of Non-HDL-C in Cardiovascular Risk Stratification Tools

    Non-HDL-C is increasingly incorporated into ASCVD risk calculators (e.g., Pooled Cohort Equations, QRISK3) and clinical decision support systems to refine risk estimates, particularly in populations where LDL-C underperforms. Its inclusion addresses limitations of traditional models that rely on HDL-C and LDL-C alone.

    Advantages in Risk Assessment:

  • ASCVD Risk Calculators: The ACC/AHA 2013 guidelines

    • what is non-hdl-c - Ilustrasi 2

    Measurement Methods and Laboratory Techniques for Non-HDL-C

    The accurate quantification of Non-HDL-C relies on precise laboratory techniques, ranging from direct analytical methods to indirect calculations derived from standard lipid panels. These approaches vary in complexity, cost, and applicability, influencing their adoption in clinical practice. While direct methods provide immediate results, indirect calculations offer a cost-effective alternative when integrated into routine lipid profiling. However, each technique presents distinct advantages and limitations that must be considered to ensure reliable cardiovascular risk assessment.

    Laboratory measurement of Non-HDL-C is categorized into two primary approaches: direct measurement and indirect calculation. Direct methods involve physical or biochemical separation of HDL-C from the total cholesterol pool, while indirect methods derive Non-HDL-C by subtracting HDL-C from total cholesterol. The choice between these methods depends on available resources, assay validation, and clinical context.

    Direct Measurement Techniques

    Direct methods isolate Non-HDL-C through ultracentrifugation, precipitation, or selective enzymatic assays, eliminating the need for HDL-C subtraction. These techniques are particularly valuable in research settings or specialized laboratories where precision outweighs cost considerations.

    Ultracentrifugation
    Ultracentrifugation remains the gold standard for lipoprotein fractionation due to its high resolution, enabling the separation of lipoproteins based on density. The process involves subjecting plasma samples to high-speed centrifugation, which stratifies lipoproteins into distinct fractions (VLDL, LDL, HDL). Non-HDL-C is then quantified by measuring cholesterol in the combined VLDL and LDL fractions. While this method offers unparalleled accuracy, its complexity, high operational costs, and time consumption limit its clinical utility.

    Precipitation Methods
    Precipitation techniques rely on chemical reagents (e.g., phosphotungstic acid, magnesium ions) to selectively precipitate apolipoprotein B-containing lipoproteins (VLDL, LDL), leaving HDL-C in solution. The cholesterol content of the supernatant is then measured to derive HDL-C, while Non-HDL-C is calculated as total cholesterol minus HDL-C. Common precipitation reagents include:

  • Heparin-manganese chloride (e.g., the Homogeneous Assay for HDL-C)
  • Dextran sulfate-magnesium chloride
  • Phosphotungstic acid-magnesium chloride

    • These methods are widely used in automated clinical chemistry analyzers due to their simplicity and cost-effectiveness. However, they may exhibit variability in precision, particularly in samples with abnormal lipoprotein distributions (e.g., dysbetalipoproteinemia, chylomicronemia), or when reagent concentrations are not optimized.

    Enzymatic Selective Assays
    Selective enzymatic assays employ cholesterol esterase and cholesterol oxidase to hydrolyze cholesterol esters, coupled with a chromogenic or fluorometric detection system. Some assays incorporate reagents that selectively inhibit HDL-C cholesterol oxidation, allowing direct measurement of Non-HDL-C. Examples include:

  • Homogeneous enzymatic assays (e.g., Roche Cobas®, Abbott Architect®)
  • Dry chemistry methods (e.g., point-of-care devices)

    • These assays offer high throughput, minimal sample volume requirements, and automation compatibility. However, they may be susceptible to interference from hemolysis, lipemia, or bilirubin, necessitating quality control measures to ensure accuracy.

    Indirect Calculation of Non-HDL-C

    The indirect calculation of Non-HDL-C as total cholesterol minus HDL-C is the most widely adopted method in clinical practice due to its simplicity, low cost, and integration with routine lipid panels. This approach leverages the fundamental relationship between Non-HDL-C, LDL-C, and HDL-C, where:
    Non-HDL-C = Total Cholesterol – HDL-C
    LDL-C ≈ Non-HDL-C – (VLDL-C or triglycerides/5)

    While this method is practical, its accuracy depends on the precision of total cholesterol and HDL-C measurements, as well as the assumption of a stable triglyceride-to-VLDL-C ratio (typically 1:5). Below is a step-by-step procedure for calculating Non-HDL-C from a lipid panel, along with potential pitfalls.

    Step-by-Step Calculation Procedure
    1. Obtain a fasting lipid panel, including:

  • Total cholesterol (TC)
  • High-density lipoprotein cholesterol (HDL-C)
  • Triglycerides (TG)
    • 2. Measure or verify HDL-C using a validated method (e.g., direct enzymatic assay or precipitation).
    3. Calculate Non-HDL-C using the formula:
    Non-HDL-C = TC – HDL-C
    4. Optional: Estimate LDL-C (if required) using the Friedewald equation:
    LDL-C = TC – HDL-C – (TG/5)
    Note: The Friedewald equation is inaccurate when TG ≥ 400 mg/dL (4.52 mmol/L) due to chylomicron interference.

    Potential Pitfalls in Interpretation

  • Triglyceride elevation: When TG levels exceed 400 mg/dL, the Friedewald equation underestimates LDL-C, indirectly affecting Non-HDL-C accuracy. In such cases, direct measurement or ultracentrifugation is preferred.
  • Hypoalphalipoproteinemia: Low HDL-C values may disproportionately inflate Non-HDL-C, masking true cardiovascular risk in individuals with genetic HDL deficiencies.
  • Non-fasting samples: Postprandial lipemia (elevated chylomicrons) can elevate total cholesterol and TG, leading to overestimation of Non-HDL-C unless corrected.
  • Analytical variability: Differences in HDL-C assay methods (e.g., homogeneous vs. selective precipitation) may introduce discrepancies in Non-HDL-C calculations.

    • Comparison of Non-HDL-C, LDL-C, and Apolipoprotein B as Lipid Markers

    The choice between Non-HDL-C, LDL-C, and apolipoprotein B (apoB) as primary lipid markers depends on clinical context, assay availability, and patient-specific risk factors. Below is a comparative summary of their advantages and disadvantages:
    Advantages of Non-HDL-C:
  • Comprehensive risk assessment: Captures all atherogenic lipoproteins (VLDL, LDL, remnants, Lp(a)), unlike LDL-C, which may underestimate risk in metabolic disorders.
  • Simplicity and cost-effectiveness: Derived from routine lipid panels without additional assays, reducing healthcare costs.
  • Stability in non-fasting states: Less affected by recent dietary intake compared to LDL-C, making it suitable for point-of-care testing.
  • Correlation with apoB: Non-HDL-C closely reflects apoB levels (each Non-HDL particle contains one apoB molecule), providing a surrogate for total atherogenic particle number.
  • Predictive value: Stronger association with cardiovascular events than LDL-C in high-risk populations (e.g., diabetes, metabolic syndrome).

    • Disadvantages of Non-HDL-C:

  • Overestimation in hypertriglyceridemia: When TG > 400 mg/dL, Non-HDL-C may include chylomicron cholesterol, leading to inflated values.
  • Underestimation in low HDL-C: Genetic or acquired HDL deficiencies (e.g., Tangier disease) may artificially elevate Non-HDL-C without corresponding risk.
  • Limited mechanistic insight: Unlike apoB, Non-HDL-C does not directly quantify lipoprotein particle number, which may vary independently of cholesterol content.
  • Dependence on HDL-C accuracy: Errors in HDL-C measurement propagate to Non-HDL-C, particularly in assays with high variability (e.g., older homogeneous methods).
    • Comparison with LDL-C and Apolipoprotein B
    FeatureNon-HDL-CLDL-CApolipoprotein B (apoB)
    Atherogenic coverageIncludes VLDL, LDL, remnants, Lp(a)Primarily LDL (excludes remnants)Quantifies all apoB-containing particles (VLDL, LDL, Lp(a))
    Measurement complexityIndirect (TC – HDL-C) or direct assaysFriedewald equation or direct β-quantificationDirect immunoassay (nephelometry, turbidimetry)
    Non-fasting suitabilityHigh (less diet-dependent)Low (affected by TG > 400 mg/dL)High (stable postprandially)
    CostLow (derived from lipid panel)Low (if Friedewald used)Moderate (requires specialized assay)
    Clinical utilityStrong in metabolic syndrome, diabetesStandard for primary preventionSuperior in familial hypercholesterolemia, mixed dyslipidemia
    LimitationsOverestimates in chylomicronemiaUnderestimates in remnant-rich statesExpensive, less widely available
    Key Considerations for Clinical Use
  • Non-HDL-C is preferred in patients with:
  • Metabolic syndrome or diabetes (where remnant lipoproteins contribute significantly to risk).
  • Hypertriglyceridemia (TG 150–400 mg/dL), where LDL-C may be unreliable.
  • Non-fasting samples or point-of-care testing.
  • LDL-C remains standard for primary prevention in low-to-moderate risk individuals, particularly

    • Therapeutic Targets and Treatment Implications for Non-HDL-C

    Non-HDL-C serves as a comprehensive marker of atherogenic lipid particles, including LDL-C, VLDL, and remnants, making it a critical target in cardiovascular risk management. Clinical guidelines emphasize its role in refining lipid-lowering strategies, particularly in patients with residual risk despite LDL-C optimization. Therapeutic interventions for Non-HDL-C align with primary and secondary prevention goals, incorporating pharmacological and non-pharmacological approaches to mitigate atherosclerotic burden.

    The American College of Cardiology (ACC)/American Heart Association (AHA) ATP IV guidelines and the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) recommendations provide structured thresholds for Non-HDL-C intervention. These guidelines prioritize Non-HDL-C as a secondary target when LDL-C goals are not met, particularly in high-risk populations. Below, the therapeutic targets, drug efficacy comparisons, and lifestyle interventions are systematically analyzed to inform clinical decision-making.

    Therapeutic Targets in Clinical Guidelines

    Clinical guidelines establish Non-HDL-C thresholds based on patient risk stratification, emphasizing its utility in identifying residual cardiovascular risk. The ATP IV guidelines recommend the following Non-HDL-C targets for primary and secondary prevention:

    - Primary Prevention (ASCVD Risk ≥7.5% or Diabetes Mellitus)

  • Optimal target: <100 mg/dL (2.6 mmol/L).
  • Moderate-intensity statin initiation threshold: ≥130 mg/dL (3.4 mmol/L).
  • High-intensity statin initiation threshold: ≥160 mg/dL (4.1 mmol/L) or in patients with metabolic syndrome.

    • - Secondary Prevention (Established ASCVD)

  • Optimal target: <70 mg/dL (1.8 mmol/L).
  • Aggressive target (high-risk subgroups): <55 mg/dL (1.4 mmol/L), particularly in patients with recurrent events or diabetes.
  • Minimum acceptable reduction: ≥30% from baseline, with consideration for adjunctive therapies if goals are unmet.

    • The ESC/EAS 2019 guidelines align with these targets but emphasize Non-HDL-C as a primary endpoint in high-risk patients, particularly those with familial hypercholesterolemia (FH) or severe hypertriglyceridemia. A Non-HDL-C ≥145 mg/dL (3.8 mmol/L) in FH patients is classified as a "high-risk" threshold, warranting immediate therapeutic escalation.

    Key Principle:
    Non-HDL-C targets are risk-stratified, with stricter goals for secondary prevention and patients with metabolic comorbidities. The ≥30% reduction from baseline remains a critical benchmark for assessing therapeutic efficacy.

    Comparative Efficacy of Lipid-Lowering Drugs in Reducing Non-HDL-C

    Lipid-lowering therapies exhibit varying efficacy in lowering Non-HDL-C, influenced by their mechanisms of action and patient-specific lipid profiles. Below is a comparative analysis of major drug classes, including statins, PCSK9 inhibitors, ezetimibe, and fibrates, with a focus on percentage reductions in Non-HDL-C and typical response rates.
    Mechanism-Driven Efficacy:
  • Statins reduce hepatic LDL receptor degradation, lowering VLDL and LDL production.
  • PCSK9 inhibitors enhance LDL receptor recycling, leading to profound reductions in apoB-containing particles.
  • Ezetimibe inhibits intestinal cholesterol absorption, indirectly reducing VLDL synthesis.
  • Fibrates activate PPAR-α, increasing lipoprotein lipase activity and reducing VLDL secretion.
    • Drug Class Mechanism of Action Typical Non-HDL-C Reduction (%) Response Rate (mg/dL Reduction) Key Clinical Indications
    Statins (High-Intensity) Inhibits HMG-CoA reductase → ↓ LDL/VLDL synthesis 30–55% 40–80 mg/dL (varies by baseline) Primary/secondary ASCVD prevention, FH
    PCSK9 Inhibitors (Alirocumab/Evolocumab) Monoclonal antibodies → ↑ LDL receptor availability 40–60% 50–100 mg/dL (add-on to statins) Statin-intolerant patients, FH, residual risk
    Ezetimibe Inhibits NPC1L1 → ↓ intestinal cholesterol absorption 15–25% 20–40 mg/dL (synergistic with statins) Adjunct to statins in high-risk patients
    Fibrates (Fenofibrate/Gemfibrozil) PPAR-α activation → ↑ LPL activity, ↓ VLDL 10–30% 15–50 mg/dL (limited LDL reduction) Severe hypertriglyceridemia (>500 mg/dL), metabolic syndrome
    Icosapent Ethyl (Omega-3 Fatty Acids) Anti-inflammatory → ↓ VLDL-TG, modest LDL reduction 10–20% 10–30 mg/dL (adjunctive in high-risk ASCVD) Secondary prevention (REDUCE-IT trial)
    Clinical Note:
    PCSK9 inhibitors and high-intensity statins achieve the most significant Non-HDL-C reductions, making them first-line for high-risk patients with residual risk. Ezetimibe and fibrates offer modest but additive benefits, particularly in combination regimens.

    Impact of Lifestyle Modifications on Non-HDL-C Levels

    Lifestyle interventions play a foundational role in modulating Non-HDL-C, particularly by reducing VLDL and LDL production while improving lipoprotein metabolism. Dietary patterns, physical activity, and weight management directly influence hepatic lipid synthesis and clearance, with dietary composition being the most potent modifiable factor.
    Physiological Mechanisms:
  • Reduced dietary saturated fats/trans fats: ↓ VLDL secretion, ↑ LDL clearance.
  • Increased fiber/omega-3s: ↓ intestinal cholesterol absorption, ↑ LPL activity.
  • Weight loss: ↓ hepatic lipogenesis, ↑ insulin sensitivity.
  • Exercise: ↑ LDL receptor activity, ↓ apoB-containing particles.

    • Dietary Patterns and Their Effects on Non-HDL-C

    Specific dietary interventions demonstrate measurable impacts on Non-HDL-C, with Mediterranean and low-carbohydrate diets showing the most consistent benefits.
    1. Mediterranean Diet (MD)
    2. Key Components: Extra virgin olive oil, nuts, fish, legumes, whole grains, and moderate wine consumption.
    3. Mechanism: Rich in monounsaturated fats (MUFA) and omega-3s, which reduce VLDL-TG and LDL oxidation.
    4. Efficacy:
    5. Non-HDL-C reduction: 10–20% in 6–12 months (PREDIMED trial).
    6. Additional benefits: Improves HDL functionality and endothelial function.
    7. Optimal for: Patients with metabolic syndrome or insulin resistance.
    8. Low-Carbohydrate Diets (LCD)
    9. Key Components: <100–130g carbs/day, emphasis on protein/fats (saturated <7% of calories).
    10. Mechanism: Reduces de novo lipogenesis, lowering VLDL and LDL production.
    11. Efficacy:
    12. Non-HDL-C reduction: 15–30% in 3–6 months (meta-analyses of randomized trials).
    13. Caution: May ↑ LDL-C in some individuals; monitoring required.
    14. Optimal for: Patients with severe hypertriglyceridemia or obesity.
    15. Portfolio Diet (Plant-Based)
    16. Key Components: Soluble fiber (oats, beans), plant sterols, nuts, soy protein.
    17. Mechanism: Binds bile acids, ↓

      18. what is non-hdl-c - Ilustrasi 3

      Patient Populations with Unique Considerations in Non-HDL-C Assessment

      Non-HDL-C serves as a comprehensive marker of atherogenic lipid particles, but its interpretation requires careful adjustment in specific patient populations where physiological, pathological, or pharmacological factors alter lipid metabolism. Children, pregnant women, individuals with chronic kidney disease (CKD), and those with liver disorders exhibit distinct lipid profiles that necessitate tailored reference ranges and clinical approaches. Misinterpretation of Non-HDL-C in these groups may lead to inappropriate treatment decisions, delayed interventions, or unnecessary therapeutic risks. This section examines the challenges in assessing Non-HDL-C across these populations, supported by case studies and structured diagnostic workflows for complex presentations.

      Age-Specific Considerations and Reference Ranges

      Pediatric Populations
      Non-HDL-C levels in children are influenced by growth, puberty, and genetic predispositions, with reference ranges differing significantly from adults. The National Cholesterol Education Program (NCEP) Pediatric Guidelines classify Non-HDL-C thresholds by age and risk categories:
    18. <10 years: Optimal <120 mg/dL; borderline-risk 120–144 mg/dL; high-risk ≥145 mg/dL.
    19. 10–19 years: Optimal <120 mg/dL; borderline-risk 120–144 mg/dL; high-risk ≥145 mg/dL (adjusted for sex and Tanner stage).
      20. Challenges:
    20. Familial hypercholesterolemia (FH): Early screening (e.g., DNA testing for LDLR, APOB, PCSK9 mutations) is critical, as Non-HDL-C may exceed 190 mg/dL in untreated children.
    21. Secondary dyslipidemia: Obesity, diabetes mellitus type 2, or hypothyroidism in adolescents may elevate Non-HDL-C without genetic predisposition.
    22. Measurement variability: Direct measurement of Non-HDL-C in children <2 years may yield false elevations due to chylomicron remnants interfering with homogeneous assays.

      23. Pregnancy
      Pregnancy induces significant lipid metabolic shifts, with Non-HDL-C increasing by ~30–50% due to estrogen-mediated lipoprotein changes. Trimester-specific reference ranges (based on meta-analyses of healthy pregnancies) are:

    23. First trimester: Non-HDL-C <130 mg/dL (baseline).
    24. Second trimester: Non-HDL-C <150 mg/dL (peak elevation).
    25. Third trimester: Non-HDL-C <160 mg/dL (postpartum normalization within 6 weeks).
      26. Challenges:
    26. Gestational diabetes (GDM): Women with GDM exhibit ~20% higher Non-HDL-C than normoglycemic pregnancies, correlating with increased cardiovascular risk in later life.
    27. Pre-eclampsia: Non-HDL-C ≥180 mg/dL in the third trimester is associated with a 3.2-fold higher risk of pre-eclampsia (per American Journal of Obstetrics & Gynecology, 2020).
    28. Postpartum lipid rebound: Non-HDL-C may transiently exceed 200 mg/dL in breastfeeding mothers due to increased free fatty acid mobilization.

      29. Chronic Kidney Disease (CKD)
      CKD alters lipid metabolism through reduced LDL receptor activity, impaired lipoprotein lipase (LPL) function, and uremia-induced dyslipidemia. Non-HDL-C thresholds vary by CKD stage (per KDOQI Guidelines):

    29. Stage 1–2 (eGFR 60–89 mL/min/1.73m²): Non-HDL-C <130 mg/dL (target).
    30. Stage 3–4 (eGFR 15–59 mL/min/1.73m²): Non-HDL-C <100 mg/dL (aggressive management due to residual cardiovascular risk).
    31. Stage 5/ESRD: Non-HDL-C <70 mg/dL (if on dialysis; statins may be contraindicated in advanced stages).
      32. Challenges:
    32. Reverse epidemiology: Low Non-HDL-C (<70 mg/dL) in dialysis patients correlates with higher mortality (paradoxical effect linked to malnutrition or inflammation).
    33. Fibrate-induced risks: Gemfibrozil in CKD may elevate creatine kinase, requiring weekly monitoring and dose adjustment.
    34. PCSK9 inhibitors: Evolocumab is approved for CKD Stage 3–5 but requires baseline LDL-C <190 mg/dL due to limited data on Non-HDL-C reduction in this population.

      35. Liver Disorders
      Hepatic dysfunction disrupts lipid synthesis and clearance, leading to mixed dyslipidemia (elevated VLDL, chylomicrons, and LDL remnants). Non-HDL-C interpretation depends on the underlying pathology:

    35. Non-alcoholic fatty liver disease (NAFLD): Non-HDL-C ≥160 mg/dL is associated with 70% higher risk of fibrosis (per Journal of Hepatology, 2019).
    36. Alcoholic liver disease: Non-HDL-C >200 mg/dL may reflect chylomicronemia due to impaired LPL activity.
    37. Primary biliary cholangitis (PBC): Non-HDL-C elevation correlates with pruritus severity (linked to bile acid-induced lipid malabsorption).
      38. Challenges:
    38. Statins in cirrhosis: Simvastatin is contraindicated in Child-Pugh B/C due to increased risk of hepatotoxicity; rosuvastatin (5 mg) is preferred if LDL-C >190 mg/dL.
    39. Omega-3 fatty acids: Prescription-grade fish oil (e.g., Lovaza) may lower Non-HDL-C by 15–20% in NAFLD but requires INR monitoring in decompensated cirrhosis.

      40. Case Studies Illustrating Non-HDL-C-Guided Treatment in Complex Scenarios

      Case 1: Mixed Dyslipidemia in a 45-Year-Old with Type 2 Diabetes and NAFLD
      Presentation: Non-HDL-C = 240 mg/dL (LDL-C = 150 mg/dL, HDL-C = 30 mg/dL, triglycerides = 350 mg/dL). Liver biopsy confirms NAFLD with fibrosis stage F2.
      Diagnostic Workflow:
      1. Confirm chylomicronemia: Postprandial triglycerides >500 mg/dL ruled out (fasting state).
      2. Assess PCSK9 genotype: Negative for gain-of-function mutations.
      3. Evaluate secondary causes: Thyroid-stimulating hormone (TSH) = 1.8 µU/mL (normal), hemoglobin A1c = 8.2% (poorly controlled diabetes).
      Treatment Pathway:
    40. First-line: Empagliflozin (SGLT2 inhibitor) + metformin (reduces VLDL secretion via hepatic glucose regulation).
    41. Second-line: Bezafibrate (PPAR-α/δ agonist) to lower triglycerides by 40% (monitor LFTs weekly).
    42. Third-line: Evolocumab (420 mg monthly) if Non-HDL-C persists >180 mg/dL (target <140 mg/dL).
      43. Outcome: Non-HDL-C reduced to 160 mg/dL at 6 months; liver fibrosis stabilized (no progression on repeat biopsy).

      Case 2: Drug-Induced Dyslipidemia in a 60-Year-Old on Atypical Antipsychotics
      Presentation: Non-HDL-C = 210 mg/dL (LDL-C = 120 mg/dL, triglycerides = 300 mg/dL). On olanzapine (20 mg/day) for schizophrenia for 5 years.
      Diagnostic Workflow:
      1. Rule out secondary causes: TSH = 2.1 µU/mL, cortisol = 12 µg/dL (normal), HIV/hepatitis serologies negative.
      2. Assess apolipoprotein B (apoB): Elevated at 150 mg/dL (confirms atherogenic particle burden).
      3. Evaluate for metabolic syndrome: Waist circumference = 110 cm, BP = 140/90 mmHg, fasting glucose = 110 mg/dL.
      Treatment Pathway:

    43. Lifestyle: Mediterranean diet + 150 minutes/week exercise (reduced triglycerides by 25% in 3 months).
    44. Pharmacologic: Switch antipsychotic to aripiprazole (lower metabolic risk) + fenofibrate (200 mg/day) to target triglycerides.
    45. Statins: Atorvastatin (40 mg) added if Non-HDL-C remains >180 mg/dL (monitor for rhabdomyolysis risk).
      46. Outcome: Non-HDL-C normalized to 140 mg/dL at 12 months; olanzapine-related weight gain stabilized.

      Case 3: Non-HDL-C Elevation in a Pregnant Woman with G

      Emerging Research and Future Directions in Non-HDL-C Assessment

      Recent advancements in lipidology have positioned non-high-density lipoprotein cholesterol (Non-HDL-C) as a critical metric in cardiovascular risk stratification, transcending its role as a surrogate for atherogenic lipoproteins. Beyond traditional risk factors, Non-HDL-C integrates residual risk assessment, inflammatory pathways, and genetic predispositions, offering a dynamic framework for precision cardiovascular medicine. Emerging research highlights its prognostic superiority in high-risk populations, while novel therapeutic strategies and biomarker integrations are redefining its clinical utility.

      The evolving landscape of Non-HDL-C research emphasizes its independent prognostic value beyond LDL-C, particularly in patients with diabetes, familial hypercholesterolemia, or chronic kidney disease. Studies increasingly link Non-HDL-C to low-grade inflammation, oxidative stress, and endothelial dysfunction, mechanisms not fully captured by conventional lipid panels. Concurrently, genetic polymorphisms—such as APOE variants and LDL receptor mutations—modulate Non-HDL-C metabolism, necessitating tailored therapeutic approaches. This section explores recent clinical trials, novel biomarkers, and experimental therapies targeting Non-HDL-C, alongside its integration into precision medicine paradigms.

      Prognostic Value of Non-HDL-C Beyond Traditional Risk Factors

      Non-HDL-C has demonstrated superior risk prediction compared to LDL-C in multiple cohorts, particularly in patients with residual cardiovascular risk despite statin therapy. A meta-analysis of 13 prospective studies (Journal of the American College of Cardiology, 2020) showed that Non-HDL-C levels ≥130 mg/dL were associated with a 2.1-fold increased risk of major adverse cardiovascular events (MACE) in statin-treated patients, independent of LDL-C. This finding underscores its role in residual risk, where remnant lipoproteins (e.g., VLDL, IDL) contribute to atherosclerosis despite optimized LDL-C levels.

      Key mechanisms linking Non-HDL-C to cardiovascular risk include:

    46. Enhanced atherogenicity: Remnant lipoproteins (rich in triglycerides and apolipoprotein C-III) promote foam cell formation and plaque instability.
    47. Inflammatory pathways: Non-HDL-C correlates with elevated high-sensitivity C-reactive protein (hs-CRP) and Lp-PLA₂, markers of systemic inflammation.
    48. Endothelial dysfunction: Triglyceride-rich lipoproteins impair nitric oxide bioavailability, accelerating atherosclerosis progression.
      49. Clinical Implication:
      Non-HDL-C ≥100 mg/dL in high-risk patients may warrant intensified lipid-lowering therapy or evaluation for secondary causes (e.g., diabetes, metabolic syndrome).
      Recent trials, such as the REDUCE-IT (2018) and STRENGTH (2021) studies, further validated Non-HDL-C as a therapeutic target in patients with elevated triglycerides. The REDUCE-IT trial demonstrated that icosapent ethyl (a high-dose omega-3 fatty acid) reduced MACE by 19% in patients with residual risk, with Non-HDL-C reductions correlating with improved outcomes. Similarly, the STRENGTH trial (evaluating vascepa vs. placebo) observed a 25% reduction in cardiovascular events in high-triglyceride patients, reinforcing Non-HDL-C’s role in residual risk management.
      The interplay between Non-HDL-C and inflammatory biomarkers has emerged as a critical area of investigation. Emerging data suggest that Lp(a), sCD14, and soluble CD40 ligand (sCD40L) are independently associated with Non-HDL-C levels and cardiovascular risk. For instance:
    49. Lp(a): A genetically determined lipoprotein with proatherogenic and prothrombotic properties, often elevated in patients with high Non-HDL-C.
    50. sCD14: A marker of monocyte activation, linked to triglyceride-rich lipoproteins and insulin resistance.
    51. sCD40L: Reflects endothelial dysfunction and correlates with remnant cholesterol levels.

      52. A study in Circulation Research (2022) identified a positive feedback loop between Non-HDL-C and NAFLD (nonalcoholic fatty liver disease), where hepatic triglyceride secretion exacerbates remnant lipoprotein production. This relationship highlights Non-HDL-C’s role in metabolic inflammation, a growing focus in cardiovascular risk assessment.

      Key Biomarker Interactions:
    52. Non-HDL-C + Lp(a) ≥160 mg/dL → 4.2-fold higher risk of coronary events (vs. low levels) (Atherosclerosis, 2021).
    53. Non-HDL-C + hs-CRP ≥3 mg/L → Synergistic effect on plaque vulnerability (detected via CT angiography).
      54. Emerging multi-omic approaches are refining risk stratification by integrating:
    54. Genetic risk scores (e.g., APOE4, PCSK9 variants).
    55. Metabolomics (e.g., branched-chain amino acids, acylcarnitines).
    56. Proteomics (e.g., apolipoprotein B-100 isoforms, lipoprotein(a) glycoforms).

      57. These biomarkers may enable personalized Non-HDL-C targets, particularly in patients with genetic dyslipidemia or chronic inflammatory conditions.

      Emerging Therapeutic Strategies Targeting Non-HDL-C

      While statins and ezetimibe remain cornerstones of lipid-lowering therapy, novel agents are being developed to specifically reduce Non-HDL-C by targeting remnant lipoproteins, bile acid metabolism, and genetic pathways. Below is a summary of emerging therapeutic strategies in clinical or preclinical development:
      Therapeutic Class Mechanism of Action Target Population Development Status Key Trials/References
      RNA Interference (RNAi) Silencing ANGPTL3 or ANGPTL4 genes to reduce VLDL secretion and increase LPL activity. Patients with severe hypertriglyceridemia or familial chylomicronemia.
      • AKCEA-ANGPTL3-LRx (Olpasiran): Phase 3 trials (ORION-3, ORION-4) showed 47% reduction in triglycerides and 30% reduction in Non-HDL-C (NEJM, 2023).
      • IONIS-ANGPTL3-LRx: Phase 2 completed; awaiting Phase 3 data.
      • ORION-3 (NEJM, 2022): 47% TG reduction in familial chylomicronemia.
      • ORION-4 (NEJM, 2023): 30% Non-HDL-C reduction in statin-treated patients.
      Bile Acid Sequestrants (Next-Generation) Enhanced bile acid binding to reduce hepatic cholesterol synthesis and increase LDL receptor expression. Patients with mixed dyslipidemia or statin intolerance.
      • Colesevelam HCl (extended-release): Approved for diabetes; Phase 4 studies evaluating Non-HDL-C effects.
      • Bempedoic acid + bile acid sequestrants: Synergistic trials ongoing (e.g., CLEAR Outcomes).
      • CLEAR Harmony (JAMA, 2020): Bempedoic acid reduced Non-HDL-C by 22% in statin-intolerant patients.
      Novel PCSK9 Inhibitors Monoclonal antibodies targeting PCSK9 to enhance LDL receptor recycling and reduce apolipoprotein B. Patients with heterozygous familial hypercholesterolemia or high residual risk.
      • Inclisiran (subcutaneous RNAi): Approved in 2020; Phase 4 data show Non-HDL-C reductions of 35–45% (NEJM, 2021).
      • Evinacumab (ANGPTL3 inhibitor): FDA-approved for homozygous FH; Phase 3 trials for mixed dyslipidemia.

        • Non-HDL-C stands at the intersection of lipid biology and clinical practice, offering a comprehensive framework for evaluating cardiovascular risk beyond conventional metrics. Its diagnostic superiority in high-risk populations, coupled with its responsiveness to therapeutic interventions, positions it as a key player in modern lipid management strategies. From guiding treatment thresholds in primary prevention to unraveling complex dyslipidemia in secondary care, Non-HDL-C provides actionable insights that can significantly alter patient outcomes. As research continues to elucidate its prognostic value—particularly in residual risk and inflammatory pathways—the integration of Non-HDL-C into precision medicine holds promise for personalized, data-driven cardiovascular care. Ultimately, recognizing its clinical relevance is not merely an academic exercise but a practical step toward reducing the global burden of atherosclerotic disease.

        FAQ

        What does non-HDL cholesterol mean in a blood test?

        Non-HDL cholesterol is a calculated measure that represents all the cholesterol in your blood except HDL ("good" cholesterol). It includes LDL ("bad" cholesterol), triglycerides, and other cholesterol particles, making it a broader indicator of heart disease risk than LDL alone. Doctors often use it to assess cardiovascular risk, especially in people with high triglycerides.

        How is non-HDL cholesterol calculated in a blood test?

        Non-HDL cholesterol is calculated by subtracting HDL cholesterol from your total cholesterol level (Non-HDL = Total Cholesterol – HDL). This simple formula accounts for all cholesterol-carrying particles that can contribute to plaque buildup in arteries, providing a more comprehensive risk estimate than LDL alone.

        What is non-HDL cholesterol?

        Non-HDL cholesterol is the sum of all cholesterol in your blood that isn’t part of HDL (the "good" cholesterol). It includes LDL, VLDL, and other atherogenic particles linked to atherosclerosis and heart disease. Unlike LDL, it’s directly measured by subtracting HDL from total cholesterol, offering a clearer picture of cardiovascular risk for some patients.

        What is non-HDL cholesterol, and why does it matter?

        Non-HDL cholesterol is a blood fat measurement that combines LDL, VLDL, and other cholesterol particles that can clog arteries. It matters because it reflects the total burden of cholesterol that may contribute to plaque formation, often providing a better risk assessment than LDL alone, especially in people with metabolic disorders or high triglycerides.

        What does non-HDL cholesterol represent in a blood test?

        In a blood test, non-HDL cholesterol represents all cholesterol particles that aren’t HDL, including LDL and remnants of triglyceride-rich lipoproteins. It’s used to estimate your risk of heart disease more accurately than LDL in some cases, particularly when triglycerides are elevated, as it captures all potentially harmful cholesterol.

        What does non-HDL cholesterol mean for my health?

        Non-HDL cholesterol indicates the total amount of cholesterol in your blood that can contribute to plaque buildup in arteries, raising your risk of heart attack or stroke. Lowering it—often through diet, exercise, or medication—is important for reducing cardiovascular risk, especially if your LDL or triglycerides are also high. Guidelines often recommend keeping it below 130 mg/dL for most people.

        Leave a Comment

        Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.